Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Deloitte
Accenture
Colorcon
Merck
Johnson and Johnson
Federal Trade Commission
Express Scripts
Chubb
Queensland Health

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,723,734

« Back to Dashboard

Which drugs does patent 6,723,734 protect, and when does it expire?


Patent 6,723,734 protects FACTIVE and is included in one NDA. There has been one Paragraph IV challenge on Factive.

This patent has fifty-nine patent family members in thirty-seven countries.

Summary for Patent: 6,723,734

Title: Salt of naphthyridine carboxylic acid derivative
Abstract:7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-ox o-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.
Inventor(s): Kim; Ae Ri (Daejeon, KR), Lee; Jin Hwa (Daejeon, KR), Park; Ki Sook (Daejeon, KR), Choi; Jong Ryoo (Daejeon, KR), Lee; Tae Hee (Daejeon, KR), Chang; Jay Hyok (Daejeon, KR), Nam; Do Hyun (Daejeon, KR), Choi; Hoon (Daejeon, KR)
Assignee: LG Life Sciences, Ltd. (Seoul, KR)
Application Number:10/223,850
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lg Chem Ltd
FACTIVE
gemifloxacin mesylate
TABLET;ORAL021158-001Apr 4, 2003ABRXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,723,734

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea97-9840Mar 21, 1997

Non-Orange Book Patents for Patent: 6,723,734

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,700,617Salt of naphthyridine carboxylic acid derivative► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,723,734

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2198697► Subscribe
Spain2213669► Subscribe
Germany69814378► Subscribe
Germany69821147► Subscribe
Denmark0981527► Subscribe
Denmark1179533► Subscribe
Algeria2448► Subscribe
Eurasian Patent Organization199900855► Subscribe
Eurasian Patent Organization001674► Subscribe
European Patent Office0981527► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
Medtronic
UBS
Cerilliant
Merck
US Army
Boehringer Ingelheim
McKesson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot